RxDoctor Payments Data

Caroline Nettles, NP

Nurse Practitioner · Lake City, FLNPI 1518584606

Payments from drug & device makers

$8,044in general payments, 2019–2025

Across 433 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Boehringer Ingelheim$592
  • Lilly USA, LLC$526
  • AbbVie$450
  • Merck$305
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$8,044100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,044 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$102,755
Medicare patients
238
Services billed
1,719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin125$128,893
MounjaroTirzepatide80$117,869
OzempicSemaglutide88$112,284
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$70,272
EliquisApixaban56$60,100
XareltoRivaroxaban42$42,282
FarxigaDapagliflozin Propanediol46$39,184
Tresiba Flextouch U-200Insulin Degludec35$30,165
LinzessLinaclotide24$27,023
MyrbetriqMirabegron25$24,977
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$19,220
Breo ElliptaFluticasone/Vilanterol22$10,993
VascepaIcosapent Ethyl23$9,827
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$6,507
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$5,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$592$135,400137 claims
Lilly USA, LLCMounjaro$526$117,86980 claims
Novo NordiskOzempic$1,631$112,28488 claims
GSKTrelegy Ellipta, Breo Ellipta$182$81,26598 claims
PfizerEliquis$153$60,10056 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,526$58,40472 claims
Johnson & JohnsonXarelto$85$42,28242 claims
AbbVieLinzess, Synthroid$450$28,87251 claims
Astellas Pharma US IncMyrbetriq$194$24,97725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Lake City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →